Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial-Reference-Cited by-同舟云学术

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

Published:2019-10 Issue: Volume:120 Page:20-30
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Robson Mark^ORCID,Ruddy Kathryn J.^ORCID,IM Seock-Ah^ORCID,Senkus Elżbieta,Xu Binghe,Domchek Susan M.,Masuda Norikazu,Li Wei,Tung Nadine,Armstrong Anne,Delaloge Suzette,Bannister Wendy,Goessl Carsten,Degboe Arnold,Hettle Robert,Conte Pierfranco

Funder

National Cancer Institute

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Breast,2017

2. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies;Khosravi-Shahi;Asia Pac J Clin Oncol,2018

3. Psychosocial problems among younger women with breast cancer;Avis;Psycho Oncol,2004

4. Toxicity of platinum compounds;Hartmann;Expert Opin Pharmacother,2003

5. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;Robson;N Engl J Med,2017

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

2. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain;PharmacoEconomics - Open;2024-08-19

3. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7);The Breast;2024-08

4. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-05-29

5. PARP Inhibitors for Breast Cancer Treatment;JAMA Oncology;2024-05-01